Influence of moclobemide on cognitive functions of nine depressed patients: pilot trial with neurophysiological and neuropsychological indices.
Quantitative electroencephalogram (QEEG) changes induced by the acute administration of moclobemide (200 mg) in patients with major depression include a transient increase in theta-activity, a slight augmentation of alpha-activity and a sustained increase in beta-activity. This QEEG profile distinguishes moclobemide from sedative antidepressants. A 42-day treatment with 400 mg/day of the drug produces a significant decrease in the late positive-complex peak latency of the event-related potentials, suggesting a positive effect on attention and cognitive functions.
Galderisi
S
S
Department of Psychiatry, Medical School, University of Naples, Italy.
Mucci
A
A
Bucci
P
P
Mignone
M L
ML
Maj
M
M
D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001143:Arousal / Q000187:drug effects*; D001288:Attention / Q000187:drug effects*; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000523:psychology; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004569:Electroencephalography / Q000187:drug effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020912:Moclobemide; D009483:Neuropsychological Tests; D010865:Pilot Projects
D000928:Antidepressive Agents; D001549:Benzamides; D020912:Moclobemide